Author

Ryan Pelto

Observed institutions: Alexion Pharmaceuticals (United States), AstraZeneca (United States)

OpenAlex ID: A5046328878

Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis

2021 · Jonathan P. R. Monteleone, Xiang Gao, et al. · Frontiers in Neurology · 39

Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Neuromyelitis Optica Spectrum Disorder

2021 · Pratap Singh, Xiang Gao, et al. · Frontiers in Neurology · 26

Safety, pharmacokinetics, and pharmacodynamics of efzimfotase alfa, a second-generation enzyme replacement therapy: phase 1, dose-escalation study in adults with hypophosphatasia

2024 · Kathryn M Dahir, Amy Shannon, et al. · Journal of Bone and Mineral Research · 15

Pharmacokinetics of Asfotase Alfa in Adult Patients With Pediatric‐Onset Hypophosphatasia

2021 · Wei‐Jian Pan, Rajendra Pradhan, et al. · The Journal of Clinical Pharmacology · 11

Best Practices for Development and Validation of Enzymatic Activity Assays to Support Drug Development for Inborn Errors of Metabolism and Biomarker Assessment

2024 · Mitra Azadeh, Jeremy Good, et al. · The AAPS Journal · 9

2025 White Paper on Recent Issues in Bioanalysis: Redosing Patients with AAV Gene Therapy; CRS Immunogenicity Risk; Shedding Assays; NHP Studies Immunogenicity; CMC vs Bioanalytical Assays; Artificial Intelligence-Powered Genomic Pipelines for NGS ( PART 3A – Recommendations on Gene, Cell, and Vaccine Therapies Immunogenicity & Technologies; Biotherapeutics & Biosimilars Immunogenicity Assessment & Clinical Relevance PART 3B – Regulatory Agencies’ Input on Immunogenicity/Technologies of Biotherapeutics, Gene, Cell & Vaccine Therapies)

2025 · Omar Tounekti, Sophie Shubow, et al. · Bioanalysis · 4

Pharmacokinetic/pharmacodynamic properties of eculizumab support established efficacy in patients with NMOSD: findings from the phase 3 PREVENT study

2020 · Achim Berthele, Celia Oreja‐Guevara, et al. · mediaTUM (Technical University of Munich) · 3

Total Copper and Labile Bound Copper Fraction as a Selective and Sensitive Tool in the Evaluation of Wilson Disease

2024 · Joshua A Bornhorst, Anna C Bitzer, et al. · The Journal of Applied Laboratory Medicine · 2

Mitigation of pre-existing immunogenicity in ADA method development

2026 · Jihua Chen, Henry Zhao, et al. · Bioanalysis · 1

Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring

2026 · Francesco Saccà, Ryan Pelto · Annals of Clinical and Translational Neurology

A systematic approach to improve the initial success rates of bioanalytical assay transfers to contract research organizations

2025 · Ming Li, Jay Ma, et al. · Bioanalysis

P02 Development and validation of a Novel ICP-MS method to quantify different copper species in human plasma from patients with wilson disease

2022 · Aftab Ala, Tao Liang, et al. · Abstracts

Works count: 12

Citation count: 110

H-index: 5

I10-index: 4